Joan Bathon | Member of the EULAR Scientific Programme Committee; Director of the Division of Rheumatology at New York-Presbyterian Hospital…

Christopher Edwards | Professor and Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology; Musculoskeletal Research Unit…

Lenabasum is an oral, non-immunosuppressive, cannabinoid Type 2 receptor agonist that activates resolution of innate immune responses.1 In animal models of bleomycin-induced skin and lung fibrosis, lenabasum reduced inflammation and fibrosis

Ricardo Ferreira  | Chair of the EULAR Committee of Health Professionals in Rheumatology; Clinical Research Nurse and Study Coordinator…

Karen Walker-Bone |  Professor and Honorary Consultant in Occupational Rheumatology, University of Southampton; Director, Arthritis Research…

Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection affecting immunocompromised individuals…

Musculoskeletal ultrasound (MSUS) biomarkers may have an important role to play in the evaluation of individuals…

Many patients with rheumatic diseases (RMD) are diagnosed during their childbearing years.1 Historically, females with RMDs were advised to avoid pregnancy due to potential risk to both mother and fetus.

It is now accepted that sustained remission is the key treatment goal for rheumatoid arthritis (RA). The availability of biologic therapies and the use of targeted treatment strategies has led to increasing numbers of patients achieving remission; however, specific guidance for the management of patients with RA in sustained clinical remission, treated with conventional synthetic disease-modifying anti-rheumatic drugs (cs-DMARDs), is lacking.

Behçet’s syndrome (BS) was first described by Hulusi Behçet in 1931, as a definite clinical entity, the ‘triple symptom complex’, based on three prominent signs: relapsing oral apthae, genital ulcerations, and iritis.